SCHEMBL25494287

SCHEMBL25494287

Cc1cc(C(C)C)ccc1NC(=O)C(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ CETP P11597 1/20 0.41
▸ TRPA1 O75762 1/20 0.41
▸ PTGS1 P23219 1/20 0.41
▸ CACNA1C Q13936 1/20 0.41
▸ ABCC9 O60706 2/20 0.40
▸ ABCC8 Q09428 2/20 0.40
▸ KCNJ11 Q14654 2/20 0.40
▸ KCNJ8 Q15842 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ HTT P42858 1/20 0.40
▸ MAPT P10636 3/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17027092 0.83 P2RX4 (0.51) TP53ALDH1A1GAAMEN1KMT2A
SCHEMBL12190515 0.81 ALDH1A1 (0.52) ALDH1A1MEN1KMT2AL3MBTL1TRPA1
SCHEMBL25494271 0.81 MEN1 (0.45) TP53ALDH1A1GAAMEN1KMT2A
SCHEMBL18930354 0.81 TRPA1 (0.41) ALDH1A1GAAMEN1KMT2AL3MBTL1
SCHEMBL9979294 0.79 MAPT (0.52) GAAMEN1KMT2AL3MBTL1TRPA1
SCHEMBL25497035 0.77 MAPK1 (0.50) GAAMEN1KMT2ATRPA1PTGS1
SCHEMBL18922386 0.77 TYR (0.51) ALDH1A1GAAMEN1KMT2AL3MBTL1
SCHEMBL10047063 0.77 MAPT (0.52) TP53ALDH1A1GAAMEN1KMT2A
SCHEMBL18088737 0.77 POLB (0.58) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL2069902 0.77 CYP1A2 (0.58) TP53ALDH1A1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-09-07 — — US disclosed
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-07-20 — — US disclosed
US-20230158155-A1 Cell Surface Receptor Binding Compounds and Conjugates LYCIA THERAPEUTICS, INC. 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158155-A1 Cell Surface Receptor Binding Compounds and Conjugates M6PR, ASGR1, IGF2R TP53 2332/4885ALDH1A1 3655/4885GAA 83/4885
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, FCGR3B, FCGR2A TP53 262/4885ALDH1A1 4520/4885GAA 2742/4885
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, ASGR1, FCGR3B TP53 297/4885ALDH1A1 4368/4885GAA 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback